The efficacy and cost-effectiveness of a family-based economic empowerment intervention (Suubi + Adherence) on suppression of HIV viral loads among adolescents living with HIV: results from a Cluster Randomized Controlled Trial in southern Uganda

Yesim Tozan, Ariadna Capasso, Sicong Sun, Torsten B Neilands, Christopher Damulira, Flavia Namuwonge, Gertrude Nakigozi, Abel Mwebembezi, Barbara Mukasa, Ozge Sensoy Bahar, Proscovia Nabunya, Claude A Mellins, Mary M McKay, Fred M Ssewamala, Yesim Tozan, Ariadna Capasso, Sicong Sun, Torsten B Neilands, Christopher Damulira, Flavia Namuwonge, Gertrude Nakigozi, Abel Mwebembezi, Barbara Mukasa, Ozge Sensoy Bahar, Proscovia Nabunya, Claude A Mellins, Mary M McKay, Fred M Ssewamala

Abstract

Introduction: Evidence from low-resource settings indicates that economic insecurity is a major barrier to HIV treatment adherence. Economic empowerment (EE) interventions have the potential to improve adherence outcomes among adolescents living with HIV (ALWHIV) by mitigating the effects of poverty. This study aims to assess the efficacy and cost-effectiveness of a savings-led family-based EE intervention, Suubi + Adherence, aimed at improving antiretroviral therapy (ART) adherence outcomes ALWHIV in Uganda.

Methods: Adolescents (mean age 12 years at enrolment; 56% female) receiving ART for HIV at 39 health centres were randomized to Suubi + Adherence intervention (n = 358) or bolstered standard of care (BSOC; n = 344). A difference-in-differences analysis was employed to assess the change in the proportion of virally suppressed adolescents (HIV RNA viral load <40 copies/mL) over 24 months. The cost-effectiveness analysis examined how much the intervention cost to virally suppress one additional adolescent relative to BSOC from the healthcare provider perspective.

Results: At 24 months, the intervention was associated with an 8.85-percentage point [95% confidence interval (CI) 0.80 to 16.90 percentage points] increase in the proportion of virally suppressed adolescents between the study arms (p = 0.032). Per-participant costs were US$177 and US$263 for the BSOC and intervention groups respectively. The incremental cost of virally suppressing one additional adolescent was estimated at US$970 [95% CI, US$508 to 10,725] over two years.

Conclusions: Our results support the integration of family-based EE interventions into adherence-support strategies as part of routine HIV care in low-resource settings to address the underlying economic drivers of poor ART adherence among ALWHIV. Moreover, per-participant costs to achieve viral suppression do not seem prohibitive compared to other community-based adherence interventions targeted at ALWHIV in low-resource settings. Further research on combination interventions at the nexus of economic security and HIV treatment and care is needed to inform the development of feasible and scalable HIV policies and programmes.

Trial registration: ClinicalTrials.gov NCT01790373.

Keywords: ART; Cost-effectiveness analysis; HIV; SUUBI; Uganda; adolescents; economic empowerment; savings-led intervention.

© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

References

    1. Danforth K, Granich R, Wiedeman D, Baxi S, Padian N. Global mortality and morbidity of HIV/AIDS. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major infectious diseases. Washington, DC: The International Bank for Reconstruction and Development / The World Bank; 2017.
    1. Kassebaum N, Kyu HH, Zoeckler L, Olsen HE, Thomas K, Pinho C, et al. Child and Adolescent Health From 1990 to 2015. JAMA Pediatr. 2017;171(6):573–92.
    1. Enane LA, Vreeman RC, Foster C. Retention and adherence: global challenges for the long‐term care of adolescents and young adults living with HIV. Curr Opin HIV AIDS. 2018;13(3):212–9.
    1. Hanghøj S, Boisen KA. Self‐reported barriers to medication adherence among chronically ill adolescents: a systematic review. J Adolesc Health. 2014;54(2):121–8.
    1. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009;51(1):65–71.
    1. Wilson DP. HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med. 2012;9:e1001231.
    1. UNAIDS . Understanding Fast‐Track: Accelerating action to ends the AIDS epidemic by 2030. Geneva, Switzerland: UNAIDS; 2015.
    1. Shoko C, Chikobvu D. A superiority of viral load over CD4 cell count when predicting mortality in HIV patients on therapy. BMC Infect Dis. 2019;19(1):169.
    1. Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, et al. Fatal and nonfatal AIDS and non‐AIDS events in HIV‐1‐positive individuals with high CD4 cell counts according to viral load strata. AIDS. 2011;25(18):2259–68.
    1. Doyle T, Geretti AM. Low‐level viraemia on HAART: significance and management. Curr Opin Infect Dis. 2012;25(1):17–25.
    1. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014, 11:CD000011.
    1. Hudelson C, Cluver L. Factors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low‐ and middle‐income countries: a systematic review. AIDS Care. 2015;27(7):805–16.
    1. World Health Organization . Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. WHO. 2016. [cited 2020 May 26]. Available from:
    1. Ferrand RA, Simms V, Dauya E, Bandason T, Mchugh G, Mujuru H, et al. The effect of community‐based support for caregivers on the risk of virological failure in children and adolescents with HIV in Harare, Zimbabwe (ZENITH): an open‐label, randomised controlled trial. Lancet Child Adolesc Health. 2017;1(3):175–83.
    1. Mavhu W, Willis N, Mufuka J, Bernays S, Tshuma M, Mangenah C, et al. Effect of a differentiated service delivery model on virological failure in adolescents with HIV in Zimbabwe (Zvandiri): a cluster‐randomised controlled trial. Lancet Glob Health. 2020;8(2):e264–75.
    1. Bermudez LG, Ssewamala FM, Neilands TB, Lu L, Jennings L, Nakigozi G, et al. Does economic strengthening improve viral suppression among adolescents living with HIV? Results from a cluster randomized trial in Uganda. AIDS Behav. 2018;22(11):3763–72.
    1. Ssewamala FM, Karimli L, Torsten N, Wang JS‐H, Han C‐K, Ilic V, et al. Applying a family‐level economic strengthening intervention to improve education and health‐related outcomes of school‐going AIDS‐orphaned children: lessons from a randomized experiment in southern Uganda. Prev Sci. 2016;17(1):134–43.
    1. Tozan Y, Sun S, Capasso A, Shu‐Huah Wang J, Neilands TB, Bahar OS, et al. Evaluation of a savings‐led family‐based economic empowerment intervention for AIDS‐affected adolescents in Uganda: a four‐year follow‐up on efficacy and cost‐effectiveness. PLoS One. 2019;14:e0226809.
    1. Institute for Health Metrics and Evaluation . Uganda Health Data. IHME. 2020 [cited 2020 May 26]. Available from:
    1. Schuyler AC, Edelstein ZR, Mathur S, Sekasanvu J, Nalugoda F, Gray R, et al. Mobility among youth in Rakai, Uganda: trends, characteristics, and associations with behavioural risk factors for HIV. Glob Public Health. 2017;12(8):1033–50.
    1. Nabukeera‐Barungi N, Elyanu P, Asire B, Katureebe C, Lukabwe I, Namusoke E, et al. Adherence to antiretroviral therapy and retention in care for adolescents living with HIV from 10 districts in Uganda. BMC Infect Dis. 2015;15:520.
    1. Ssewamala FM, Byansi W, Bahar OS, Nabunya P, Neilands TB, Mellins C, et al. Suubi+Adherence study protocol: a family economic empowerment intervention addressing HIV treatment adherence for perinatally infected adolescents. Contemp Clin Trials Commun. 2019;16:100463.
    1. Dimick JB, Ryan AM. Methods for evaluating changes in health care policy: the difference‐in‐differences approach. JAMA. 2014;312(22):2401–2.
    1. Gertler PJ, Martinez S, Premand P, Rawlings LB, Vermeersch CMJ. Impact evaluation in practice, 2nd edn. Washington, DC: Inter‐American Development Bank and World Bank; 2016.
    1. Uganda Bureau of Statistics . Consumer Price Index Kampala, Uganda: Uganda Bureau of Statistics. Table 8: Uganda Consumer Price Index (CPI) by Income Groups and Geographical Areas. 2017 [cited 2019 Nov 10]. Available from:
    1. Bank of Uganda . Foreign exchange rates. [cited 2019 Nov 10]. Available from:
    1. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost‐effectiveness analysis alongside clinical trials II‐An ISPOR Good Research Practices Task Force report. Value Health. 2015;18(2):161–72.
    1. Husereau D, Drummond M, Petrou S. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: a report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health. 2013;16:231–50.
    1. Ssewamala FM, Dvalishvili D, Mellins CA, Geng EH, Makumbi F, Neilands TB, et al. The long‐term effects of a family based economic empowerment intervention (Suubi+Adherence) on suppression of HIV viral loads among adolescents living with HIV in southern Uganda: Findings from 5‐year cluster randomized trial. PLoS One. 2020;15:e0228370.
    1. Zürcher K, Mooser A, Anderegg N, Tymejczyk O, Couvillon MJ, Nash D, et al. Outcomes of HIV‐positive patients lost to follow‐up in African treatment programmes. Trop Med Int Health. 2017;22(4):375–87.
    1. Lamiraud K, Moatti JP. Economic implications of nonadherence to highly active antiretroviral treatment in HIV patients. Expert Opin Pharmacother. 2006;7(2):135–43.
    1. Ssewamala FM, Sperber E, Zimmerman JM, Karimli L. The potential of asset‐based development strategies for poverty alleviation in Sub‐Saharan Africa. Int J Social Welfare. 2010;19(4):433–43.
    1. National Planning Authority, Government of Uganda . Uganda Vision 2040. Government of Uganda. 2013. [cited 2021 Feb 14]. Available from:
    1. Oberjé EJ, de Kinderen RJ, Evers SM, van Woerkum CM, de Bruin M. Cost effectiveness of medication adherence‐enhancing interventions: a systematic review of trial‐based economic evaluations. Pharmacoeconomics. 2013;31(12):1155–68.
    1. Adamson B, El‐Sadr W, Dimitrov D, Gamble T, Beauchamp G, Carlson JJ, et al. The cost‐effectiveness of financial incentives for viral suppression: HPTN 065 study. Value Health. 2019;22(2):194–202.
    1. Bautista‐Arredondo S, Mane A, Bertozzi SM. Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling‐up of access to treatment: lessons from Mexico. AIDS. 2006;20(1):101–9.
    1. Over M, Marseille E, Sudhakar K, Gold J, Gupta I, Indrayan A, et al. Antiretroviral therapy and HIV prevention in india: modeling costs and consequences of policy options. Sex Transm Dis. 2006;33(10):S145–52.
    1. Evans D, Fox MP. When and how should we be measuring adherence to antiretroviral therapy in resource‐limited settings? J Clin Res HIV AIDS Prevent. 2013;1(2):24–30.
    1. Shade SB, Osmand T, Luo A, Aine R, Assurah E, Mwebaza B, et al. Costs of streamlined HIV care delivery in rural Ugandan and Kenyan clinics in the SEARCH Studys. AIDS (London, England). 2018;32(15):2179–88.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren